about
Alzheimer's disease - a neurospirochetosis. Analysis of the evidence following Koch's and Hill's criteriaMedications and DietPrevention of Alzheimer's diseaseAspirin and anti-inflammatory drugs for the prevention of dementiaAspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's diseaseAspirin for in vitro fertilisationLow-dose aspirin for in vitro fertilisationLow-dose aspirin for in vitro fertilisationIbuprofen for Alzheimer's diseaseOleuropein in olive and its pharmacological effectsNo advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studiesPremorbid cognitive testing predicts the onset of dementia and Alzheimer's disease better than and independently of APOE genotypeCyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapyNSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivoEffect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studiesNonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE StudyBrain inflammation and oxidative stress in a transgenic mouse model of Alzheimer-like brain amyloidosisPPARgamma, neuroinflammation, and diseaseInflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer's diseaseEarly correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease miceThe microglial "activation" continuum: from innate to adaptive responsesTargeting innate immunity for neurodegenerative disorders of the central nervous systemGenetic and Transcriptomic Profiles of Inflammation in Neurodegenerative Diseases: Alzheimer, Parkinson, Creutzfeldt-Jakob and TauopathiesPotential Therapeutical Contributions of the Endocannabinoid System towards Aging and Alzheimer's DiseaseThe 5-lipoxygenase pathway: oxidative and inflammatory contributions to the Alzheimer's disease phenotypeNeuroinflammation in Alzheimer's disease; A source of heterogeneity and target for personalized therapyDoes neuroinflammation fan the flame in neurodegenerative diseases?Inflammation and Alzheimer's diseaseWhat are all the things that aspirin does?Non-steroidal anti-inflammatory drugs mediate increased in vitro glial expression of apolipoprotein E proteinNeuroprotective effects of non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicalsMy health: whose responsibility? Low-dose aspirin and older peopleToo little, too late?Abeta-induced inflammatory processes in microglia cells of APP23 transgenic miceEffects of S-2474, a novel nonsteroidal anti-inflammatory drug, on amyloid beta protein-induced neuronal cell deathIdentification of a novel dehydroergosterol enhancing microglial anti-inflammatory activity in a dairy product fermented with Penicillium candidumCurcumin Ameliorates the Reduction Effect of PGE2 on Fibrillar β-Amyloid Peptide (1-42)-Induced Microglial Phagocytosis through the Inhibition of EP2-PKA Signaling in N9 Microglial CellsCyclopentenone prostaglandins suppress activation of microglia: down-regulation of inducible nitric-oxide synthase by 15-deoxy-Delta12,14-prostaglandin J2The Alzheimer pandemic: is paracetamol to blame?Short-term treatment with tolfenamic acid improves cognitive functions in Alzheimer's disease mice
P2860
Q21245230-BAB7EF3C-3509-499D-B879-A49D242988CCQ22242806-65532106-2CD7-4184-9D58-40D8B981D43AQ22248031-6860DEFC-74BC-4CF2-BE5B-C0102107058EQ24186992-12DBA250-2004-4589-90DE-FCBE98C24882Q24203739-EEE3EA68-CA26-4613-B199-DB5A6EF4E662Q24235031-64952088-67EC-4C2A-8BA2-7352E57ABF28Q24242925-DF5082F2-CC82-4F99-BDFD-14203EF07BE1Q24246885-1DD6C350-5196-4FF6-834D-27572F126D23Q24248782-3B88FF30-9426-4ADA-8968-14E6A0A5D626Q24628912-C19F5790-432B-4C28-99E8-F1B2D930C43FQ24642539-73490E1D-DB05-4625-AAB3-89BDF7F450F7Q24670639-31F43388-2447-415F-8D18-3F6705C0AF9DQ24675327-4A644709-1A7C-45A4-82B4-42010AD410A0Q24679444-595E89FD-E35B-4B7C-995E-19C831611B79Q24681261-1F75E75C-78EA-4BD4-B80B-74E4F932F96CQ24792960-715E3C0B-ADDB-4DF6-B972-259A836C460DQ24793976-A9F87DD1-AC53-4AA1-A6E9-D6342CD281C2Q24794438-A739E54A-728C-4223-AA47-82C61EF29B4FQ24803797-DF7BD029-4265-462E-A58C-AFE1EFE33AB4Q24813024-C20003B3-0E1B-403A-BFC5-CA4C7EAECC39Q24814335-C3BAB533-BBDF-4020-90B3-38297ACD731DQ26744219-8E621799-96AD-4F9B-8A88-A14C705BB075Q26767289-20DD1205-C1B7-496F-AB08-DCA0C84C3A72Q26783325-C0679116-D583-4D4B-A45D-CA8121CD76C6Q26999358-C31800BB-40F3-4171-93E4-A37403B40C8DQ27014919-D91AF881-1504-41FA-ACB0-B172541C9F82Q27498993-2BF9342B-3E3B-4B22-BF43-69AD754377A8Q28138617-4E9C76AE-903B-4BA7-8C9A-4BD5C5C57167Q28165288-105A7268-AFFE-47E0-80B1-D31792227414Q28165456-B05C7137-15A0-4917-852F-1CB7312FF9A7Q28180514-51125359-C053-4FBA-AD95-E18CA3BFF82FQ28201631-D248049B-426C-4DBB-90B2-18B5A7628431Q28211457-0BE6976D-E7B5-45C8-A170-810B01BF78EBQ28345644-9E2B31FE-BAE9-44A1-9E0B-861B3468D780Q28361095-ADECF353-4091-496D-AAB4-1C3911DD9C89Q28543968-CC83B79A-AA7F-4795-83B0-FA0FCCABACCDQ28552971-5A53CCF6-37D4-4BEB-827F-7893117FB422Q28619368-6AA7D1C3-AC9D-4370-A7D6-96652AE2FF7BQ30357019-02A1708B-8D46-42DB-B96F-69F034CE0006Q30541295-B22986FA-B0AC-41A3-AF4F-CF42D2BABEA0
P2860
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Risk of Alzheimer's disease and duration of NSAID use.
@en
Risk of Alzheimer's disease and duration of NSAID use.
@nl
type
label
Risk of Alzheimer's disease and duration of NSAID use.
@en
Risk of Alzheimer's disease and duration of NSAID use.
@nl
prefLabel
Risk of Alzheimer's disease and duration of NSAID use.
@en
Risk of Alzheimer's disease and duration of NSAID use.
@nl
P2093
P356
P1433
P1476
Risk of Alzheimer's disease and duration of NSAID use.
@en
P2093
P304
P356
10.1212/WNL.48.3.626
P407
P577
1997-03-01T00:00:00Z